Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545264 | 1.00 | TNKS (0.44) | TNKSPARP1TNKS2NOTUMSMN1; SMN2 | |
| SCHEMBL5549419 | 0.80 | TNKS (0.41) | TNKSPARP1TNKS2MEN1KMT2A | |
| SCHEMBL5549424 | 0.80 | TNKS (0.41) | TNKSPARP1TNKS2MEN1KMT2A | |
| SCHEMBL17870853 | 0.80 | MEN1 (0.44) | MEN1KMT2AHTTMAPTKDM4E | |
| SCHEMBL19747069 | 0.80 | MEN1 (0.44) | MEN1KMT2AHTTMAPTKDM4E | |
| SCHEMBL17870841 | 0.79 | PIK3CD (0.42) | KDM4EALDH1A1GAACHRM2CHRM4 | |
| SCHEMBL17870863 | 0.79 | PIK3CD (0.42) | KDM4EALDH1A1GAACHRM2CHRM4 | |
| SCHEMBL5549420 | 0.76 | TNKS (0.38) | TNKSPARP1TNKS2SMN1; SMN2MEN1 | |
| SCHEMBL5549425 | 0.76 | TNKS (0.38) | TNKSPARP1TNKS2SMN1; SMN2MEN1 | |
| SCHEMBL5549422 | 0.76 | TNKS (0.38) | TNKSPARP1TNKS2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1760054-A2 | Process for producing cyclic compound | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7038042-B2 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20050096475-A1 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| US-6864367-B2 | Process for producing cyclic compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
| US-20030040632-A1 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1266881-A1 | PROCESS FOR PRODUCING CYCLIC COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040632-A1 | Process for producing cyclic compound | CTH, DOHH, SLC39A11 | TNKS 4867/4885PARP1 3436/4885TNKS2 4714/4885 |
| US-20050096475-A1 | Process for producing cyclic compound | SLC39A11, CYP4F11, WEE1 | TNKS 4835/4885PARP1 2948/4885TNKS2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.